Amresh Kumar - Grace Therapeutics VP Management
| GRCE Stock | 3.61 0.08 2.27% |
VP
Amresh Kumar is VP Management of Grace Therapeutics
| Age | 46 |
| Address | 103 Carnegie Center, Princeton, NJ, United States, 08540 |
| Phone | 609 322 1602 |
| Web | https://www.gracetx.com |
Grace Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1084) % which means that it has lost $0.1084 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1022) %, meaning that it created substantial loss on money invested by shareholders. Grace Therapeutics' management efficiency ratios could be used to measure how well Grace Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 17, 2026, Return On Tangible Assets is expected to decline to -0.51. In addition to that, Return On Capital Employed is expected to decline to -0.22. At present, Grace Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting.Similar Executives
| Found 5 records | VP Age | ||
| CGMA CPA | RenovoRx | 68 | |
| Stephen CPA | Tvardi Therapeutics | N/A | |
| Joe Dervan | PDS Biotechnology Corp | N/A | |
| Sunitha Lakshminarayanan | Actinium Pharmaceuticals | N/A | |
| Elaina Haeuber | Actinium Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.1 | ||||
| Return On Asset | -0.11 |
Grace Therapeutics Leadership Team
Elected by the shareholders, the Grace Therapeutics' board of directors comprises two types of representatives: Grace Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grace. The board's role is to monitor Grace Therapeutics' management team and ensure that shareholders' interests are well served. Grace Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grace Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert CPA, VP Officer | ||
| Prashant Kohli, CEO Director | ||
| Amresh Kumar, VP Management | ||
| Carrie DAndrea, VP Operations |
Grace Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Grace Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.1 | ||||
| Return On Asset | -0.11 | ||||
| Current Valuation | 32.86 M | ||||
| Shares Outstanding | 14.13 M | ||||
| Shares Owned By Insiders | 27.06 % | ||||
| Shares Owned By Institutions | 25.82 % | ||||
| Number Of Shares Shorted | 38.49 K | ||||
| Price To Book | 0.89 X | ||||
| EBITDA | (16.67 M) | ||||
| Net Income | (9.57 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Grace Therapeutics is a strong investment it is important to analyze Grace Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Grace Therapeutics' future performance. For an informed investment choice regarding Grace Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Grace Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For information on how to trade Grace Stock refer to our How to Trade Grace Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Will Pharmaceuticals sector continue expanding? Could Grace diversify its offerings? Factors like these will boost the valuation of Grace Therapeutics. Market participants price Grace higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Grace Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Grace Therapeutics requires distinguishing between market price and book value, where the latter reflects Grace's accounting equity. The concept of intrinsic value - what Grace Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Grace Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Grace Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Grace Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Grace Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.